Opinion-leading Scientific Advisory Board

Paolo Micheli

Paolo is a growth factor expert and the CSO of Agomab. He spent several years conducting research at the National Cancer Institute, National Institutes of Health in Bethesda, Maryland, in the laboratory that discovered that MET is the HGF receptor in the early 1990s. Since he returned to Italy, he has been directing a translational

Torsten Dreier

Torsten is the CDO at Agomab and brings an extensive expertise in developing antibodies and antibody-based drugs with more than 20 years in the pharmaceutical industry. He has a successful track record of progressing 10 antibody products from preclinical research to clinical development, including two (Blincyto and Cablivi) that obtained marketing authorization. Prior to joining

By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.